Formidable Asset Management’s Sonnet BioTherapeutics SONN Stock Holding History

Formidable Asset Management’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-37,185	Closed	-$170K	–	411
2025 Q4	$170K	Buy	+37,185	New	+$168K	0.02%	391

Formidable Asset Management's SONN Position: Q1 2026 in Review

Formidable Asset Management sold out of Sonnet BioTherapeutics (SONN) in Q1 2026, closing a stake of 37,185 shares — an estimated $170K sold.

Formidable Asset Management first reported a position in SONN in Q4 2025 and held it in 1 quarter. The position peaked at $170K in Q4 2025. 0 funds tracked by Wall St. Rank hold SONN as of Q1 2026.

Formidable Asset Management reported no remaining Sonnet BioTherapeutics position as of Q1 2026 after selling out during the quarter.
Formidable Asset Management sold 37,185 Sonnet BioTherapeutics shares in Q1 2026, an estimated $170K.
Formidable Asset Management first reported a position in Sonnet BioTherapeutics in Q4 2025 and held it in 1 quarter.
Formidable Asset Management's Sonnet BioTherapeutics position peaked at $170K in Q4 2025.
0 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q1 2026.

Based on Formidable Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.